C

Concord Biotech Ltd
NSE:CONCORDBIO

Watchlist Manager
Concord Biotech Ltd
NSE:CONCORDBIO
Watchlist
Price: 1 518 INR 0.73%
Market Cap: 158.8B INR
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

0
Revenue
+0%
3Y
-
5Y
-
10Y
-
0
Operating Income
+0%
3Y
-
5Y
-
10Y
-
0
Net Income
+0%
3Y
-
5Y
-
10Y
-

Earnings Waterfall
Concord Biotech Ltd

Revenue
10.9B INR
Cost of Revenue
-2.7B INR
Gross Profit
8.2B INR
Operating Expenses
-4.3B INR
Operating Income
4B INR
Other Expenses
-704.5m INR
Net Income
3.3B INR

Income Statement
Concord Biotech Ltd

Rotate your device to view
Income Statement
Currency: INR
Millions
Ones
Thousands
Millions
Billions
TTM
Quarterly
Annual
TTM
Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024 Dec-2024
Revenue
Revenue
13 103
N/A
15 511
+18%
10 169
-34%
10 379
+2%
10 857
+5%
10 892
+0%
Gross Profit
Cost of Revenue
(2 735)
(3 206)
(3 342)
(2 371)
(2 605)
(2 659)
Gross Profit
10 369
N/A
12 306
+19%
6 828
-45%
8 008
+17%
8 252
+3%
8 233
0%
Operating Income
Operating Expenses
(5 826)
(6 839)
(3 047)
(4 139)
(4 208)
(4 266)
Selling, General & Administrative
(1 687)
(1 994)
(2 432)
(1 265)
(1 300)
(1 339)
Depreciation & Amortization
(804)
(939)
(536)
(537)
(537)
(535)
Other Operating Expenses
(3 335)
(3 906)
(79)
(2 337)
(2 371)
(2 392)
Operating Income
4 543
N/A
5 466
+20%
3 780
-31%
3 870
+2%
4 044
+5%
3 967
-2%
Pre-Tax Income
Interest Income Expense
(16)
9
245
(33)
(21)
(29)
Non-Reccuring Items
0
0
0
0
0
0
Gain/Loss on Disposition of Assets
0
0
0
0
0
0
Total Other Income
501
583
100
374
393
459
Pre-Tax Income
5 028
N/A
6 059
+21%
4 126
-32%
4 211
+2%
4 417
+5%
4 397
0%
Net Income
Tax Provision
(1 272)
(1 527)
(1 045)
(1 078)
(1 138)
(1 135)
Income from Continuing Operations
3 756
4 532
3 081
3 132
3 279
3 263
Net Income (Common)
3 756
N/A
4 532
+21%
3 081
-32%
3 132
+2%
3 279
+5%
3 263
-1%
EPS (Diluted)
35.9
N/A
43.28
+21%
29.45
-32%
29.95
+2%
50.86
+70%
31.19
-39%

See Also

Summary
CONCORDBIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
CONCORDBIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CONCORDBIO stock valuation using valuation multiples.
Wall Street Estimates
CONCORDBIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CONCORDBIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 254,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.